Immuron is presenting an overview of their company and investment opportunities. They have a unique oral immunotherapy platform targeting the microbiome and inflammation with potential in various indications. Their lead program is in NASH (non-alcoholic steatohepatitis), where their drug IMM-124E has shown potential in preclinical and clinical studies to reduce liver inflammation and fibrosis through its anti-LPS and regulatory T-cell promoting properties. They are also developing a vaccine against C. difficile and have an approved traveler's diarrhea drug called Travelan that is generating revenues. Immuron believes they are significantly undervalued given their pipeline, which includes programs targeting large markets like NASH estimated at $35-40 billion by